January 10, 2020
Silva MA et al. J Pathol Clin Res 2020;6(2):124-137.
Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells.
You might also be interested by
Posters
Development of a Pathologist Scoring Method to Determine Inflamed, Excluded or Desert Immune Phenotype in Carcinoma
March 5, 2025
Histopathology
More infoScientific Publications
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
January 27, 2025
Histopathology
More infoPosters
Development of a visual scoring method to determine inflamed, excluded or desert immune phenotype in Non-Small Cell Lung Cancer, Colorectal Cancer, and Urothelial Cancer
November 7, 2024
Histopathology
More infoBrochures & Infographics
Immunohistochemistry (IHC) Biomarker List
October 10, 2024
Histopathology
More info